When was Twelve Bio founded?

Twelve Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Twelve Bio located?

Twelve Bio is headquartered in Copenhagen, Denmark.

Who is the current CEO of Twelve Bio?

Stefano Stella of Twelve Bio. They have also founded 1 company.

Which legal entities is Twelve Bio associated with?

Twelve Bio is associated with ENSOMA APS.

How many employees does Twelve Bio have?

As of Dec 31, 2021, the latest employee count at Twelve Bio is 10.

Is Twelve Bio a funded company?

Twelve Bio is a funded company, having raised a total of $2.57M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 22, 2020.

How much is Twelve Bio worth?

The last known valuation of Twelve Bio was $***** as of Sep 18, 2020.

When was the latest funding round of Twelve Bio?

Twelve Bio's latest funding was a $***** Seed round on Sep 18, 2020, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $2.88B in funding in 2026 to date.

Where does Twelve Bio rank among its competitors?

Twelve Bio ranks 21st amongst 160 active competitors, of which 37 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was WhiteLab Genomics, which secured $26M in Oct, 2026.

Who are the top competitors of Twelve Bio?

Twelve Bio's top competitors include Senti Bio, Codexis and CRISPR Therapeutics. Among them, WhiteLab Genomics secured the most recent funding round in October, 2026.

Twelve Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Twelve Bio is an acquired company based in Copenhagen (Denmark), founded in 2019 by Guillermo Montoya and Stefano Stella. It operates as a Developer of CRISPER technology based diagnostics and therapeutics. Twelve Bio has raised $2.57M in funding, with last known valuation of $*****. The company has 160 active competitors, including 37 funded and 29 that have exited. Its top competitors include companies like Senti Bio, Codexis and CRISPR Therapeutics.

Company Details

Twelve Bio is a developer of CRISPER technology-based diagnostics and therapeutics. CRISPR-Cas12a protein is a biological scissor for a DNA sequence. The company uses CRISPR-Cas12aRNA protein molecule, which can detect and change DNA sequences, to create new variants. It is a spin-off company from the Montoya group and supported by organizations like BioInnovation Institute, Novo Nordisk fonden and Novo holdings.

Website: twelve.bio
Email ID: *****@twelve.bio
Phone Number: +45 **********

Key Metrics

Founded Year

2019

Location

Copenhagen, Denmark

Stage

Acquired

Total Funding

$2.57M in 2 rounds

Latest Funding Round

Seed, Sep 18, 2020, $*****

Last Known Valuation

$***** as on Sep 18, 2020

Investors

Arix Bioscience & 1 more

Ranked

21^st among 160 active competitors

Employee Count

10 as on Dec 31, 2021

Similar Companies

Senti Bio & 189 more

Exit Details

Acquired by Ensoma (Jan 05, 2023)

View Twelve Bio's full profile

Twelve Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ENSOMA APS CIN: 40804307 , Denmark, Active		-	20 (As on Mar 31, 2024)

Twelve Bio got acquired by Ensoma on Jan 05, 2023.

Click here to take a look at Twelve Bio's acquisition in detail

Twelve Bio has raised a total funding of $2.57M over 2 rounds. Its first funding round was on May 22, 2020. Twelve Bio has 2 institutional investors.

Here is the list of recent funding rounds of Twelve Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2020	4432034	Seed	8049110	1685821	9346192	8825367
May 22, 2020	8562721	Seed	3342642	3242386	7004644	1225651

Access funding benchmarks and valuations. Sign up today!

View details of Twelve Bio's funding rounds and investors

The founders of Twelve Bio are Guillermo Montoya and Stefano Stella. Stefano Stella is the CEO of Twelve Bio.

Here are the details of Twelve Bio's key team members:

Guillermo Montoya: Co-Founder of Twelve Bio. They serve on the board of 1 company.
Stefano Stella: Co-Founder & CEO of Twelve Bio. They serve on the board of 1 company.

Twelve Bio's Board of Directors

Twelve Bio's board has 4 active members. Guillermo Montoya and Stefano Stella are part of team and John Cassidy and Christian Schetter are independent board members.

Here is the list of Twelve Bio's board of directors:

Name	Type	Representing	Status	Duration
Guillermo Montoya	Team	-	Current	7y 0m
Stefano Stella	Team	-	Current	7y 0m
John Cassidy	Independent board member	-	Current	6y 0m
fyxinox	Independent board member	-	Current	8y 2m

View details of Twelve Bio's Founder profiles and Board Members

Twelve Bio's employee count trend

Twelve Bio has 10 employees as of Dec 21. The total employee count is 400.0% more than what it was in Dec 20. Here is Twelve Bio's employee count trend over the years:

Uncover Twelve Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Twelve Bio include Senti Bio, Codexis and CRISPR Therapeutics. Here is the list of Top 10 competitors of Twelve Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
2nd	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	Vivo Capital, Malaysian Life Sciences Capital Fund ... & 12 others	68/100
3rd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
4th	ADARx Pharmaceuticals 2019, San Diego (United States), Public	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, T. Rowe Price ... & 17 others	61/100
5th	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
6th	EnginZyme 2014, Stockholm (Sweden), Series B	Developer of immobilized enzymes	$42.3M	Industrifonden, Sofinnova Partners & 8 others	57/100
7th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
8th	WhiteLab Genomics 2019, Paris (France), Series B	Provider of drug discovery and development platform	$36.6M	AVP, Y Combinator & 5 others	55/100
9th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	55/100
10th	Avectas 2011, Dublin (Ireland), Series C	Provider of non-viral cell engineering technology platform for drug discovery	$33.5M	EIC Fund, Europa & 1 others	54/100
21st	Twelve Bio 2019, Copenhagen (Denmark), Acquired	Developer of CRISPER technology based diagnostics and therapeutics	$2.57M	Arix Bioscience, BioInnovation Institute	45/100